2月27日，A股医疗板块全天飘红，全市场规模最大医疗ETF（512170）盘中上探1.14%，成功收复年 线，成交3.84亿元。场内持续溢价交易，显示买盘态度积极，此前3日512170累获逾1.9亿元净申购。 | 分时 多日 1分 5分 * | | | | F9 盘前盘后 徽加 九特 画线 工具 @ (2 )> | | | | | 顾疗ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 512170医疗ETF] 15:00 价 0.355 通联 0.003(0.85%) 均价 0.354 1 512170(医疗器价交易 | | | | 0.354 +0.002 +0.57% | | 512170 | | | | 0.355 | | A NAT THE | | A CAL WHEY YOUNG WALL OLT OF O | | | SSE CNY 15:00:16 图布 查看L2全覆 | | 通政人员干 | | | | | | | | | | 净值走势 | | 华宝中让医疗L ...

10% 医药生物 沪深300 -5% 0% 5% 10% 医药生物 沪深300 标配（维持） 医药生物行业双周报（2026/2/13-2026/2/26） 静待板块回暖 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 -35% -35% -30% -20% 0% 20% 医药生物 沪深300 -15% -10% -5% 0% 5% 10% 医药生物 沪深300 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： -40% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 -30% -25% -20% xiexiongxiong@dgzq.com.cn -35% 资料来源：iFind，东莞证券研究所 相关报告 -30% -25% -20% -15% -10% 5% -25% -20% -15% -10% -5% 0% -35% 2026 年 2 月 27 日 医药生物（申万）指数走势 证 券 研 ...

来源：金融人事mini 天津分行行长周亮球，任广东省分行党委书记、行长。曾任进出口银行湖北省分行行长助理、副行长， 2018年8月任辽宁省分行行长，2022年任天津分行行长。 北京行行长王智洁，拟任总行内控合规部总经理。曾任进出口银行北京分行行长助理，2021年8月任总 行主权客户部（优惠贷款部）总经理，2025年3月起任北京分行行长。 广东省分行行长刘亚，拟任北京分行行长。曾任进出口银行总行信贷部副总经理，交通运输融资部副总 经理，主权客户部总经理；2020年8月起任广东省分行行长。 总行专项融资部副总经理张炬，任天津分行党委书记。曾任进出口银行圣彼得堡代表处首席代表，总行 交通运输融资部副总经理。 据"口行组轩"消息，2026年1月份，进出口银行相继新任命了吉林、河北、内蒙古、山西、贵州、辽宁 等六家省分行党委书记和总行多部门总经理。 春节后，进出口银行中层干部调整持续，又有多家省级分行行长出现变动，详情如下： 宁波分行行长黄华丽，任总行金融机构部（转贷部、外事管理中心）总经理。曾任进出口银行湖北省分 行行长助理，2020年2月任浙江省分行副行长，2023年2月任宁波分行行长。 总行金融机构部（转贷部、外 ...

脑机接口+CRO概念+传感器+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 2、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站式服务。 来源：新浪证券-红岸工作室 2月27日，美好医疗涨3.89%，成交额4.59亿元，换手率3.98%，总市值177.89亿元。 异动分析 技术面：筹码平均交易成本为32.71元 该股筹码平均交易成本为32.71元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 31.02，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 3、根据2025年9月22日互动易：公司自研压力传感器和NO电化学传感器分别用于肺功能仪和哮喘检测 仪产品，毫米级电磁定位传感器也在自主开发中，相关产品的业务规模较小。 4、公司的主营业务是医疗器械精密组件及产品的设计开发、制造和销售。公司主要产品为家用呼吸机 组件、人工植入耳蜗组件和 ...

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Core Viewpoint - The article discusses the recent surge in interest around the "space photovoltaic" concept, driven by Elon Musk's statements, and highlights the regulatory scrutiny faced by companies attempting to capitalize on this trend through misleading disclosures [1][2]. Group 1: Regulatory Actions - Several companies in the photovoltaic and lithium battery sectors have received regulatory warnings for improper disclosures since February, including Shuangliang Energy and Trina Solar, which were cautioned for misleading statements regarding their collaborations with SpaceX [1][2]. - The Shanghai Stock Exchange emphasized the need for accurate and complete information disclosure, particularly in light of heightened market interest in collaborations between Chinese photovoltaic companies and SpaceX [4]. Group 2: Market Reactions - Following Musk's endorsement of "space photovoltaics" at the World Economic Forum, the photovoltaic sector saw a significant market reaction, with a total market capitalization increase of 178.5 billion yuan on January 23 [2]. - Companies like Shuangliang Energy experienced a sharp stock price increase after announcing orders related to SpaceX, but subsequent regulatory warnings led to a rapid decline in their stock prices, highlighting the volatility associated with speculative trading [3][6]. Group 3: Investor Guidance - Investors are advised to critically assess the credibility of claims made by companies regarding their involvement in high-profile projects, as many companies lack objective evidence to support their assertions [7]. - The article suggests that investors should evaluate the alignment between a company's current capabilities and its ambitious claims, particularly in sectors like commercial space and AI, to avoid becoming "high-priced buyers" [7]. Group 4: Corporate Governance and Compliance - The article stresses that effective market value management should focus on compliance and value creation rather than mere stock price manipulation, urging companies to enhance governance and profitability before engaging in public disclosures [8].

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

31年、19个月——这是我国国内有效发明专利数量，分别达到第一个、第五个100万件所用的时 间。 时间之变，映照理念之变、发展之变。回眸"十四五"时期，一个"最"字，世界瞩目：我国成为全球 拥有国内有效发明专利最多的国家，截至目前总数超532万件。 人工智能、量子科技、生物制造、脑机接口……截至2025年底，我国国内高价值发明专利中，七成 来自战略性新兴产业。保护知识产权就是保护创新。从人工智能服务千行百业，到风电技术推动绿色转 型发展，532万件专利正成为连接创新与市场的纽带，为加快发展新质生产力注入澎湃动能。 由多向优、攀高向新，展望"十五五"，中国特色知识产权发展之路渐次铺展，风光正好。（陈世 涵） 于布局看，519家国家级知识产权公共服务机构，遍布大江南北，实现省级层面全覆盖；从机制 看，申请端、代理端、审查端协同发力，推动创新从量的积累迈向质的飞跃。 创新的价值，要落脚于高质量发展的质效。 数量的跃迁，不是简单的数字叠加，而是创新生态持续优化的必然。 ...

Group 1 - In February, nearly 240 listed companies were surveyed by various institutions, with over half achieving positive returns during the same period, and some stocks seeing cumulative gains exceeding 80% [1] - The mechanical equipment and electronics sectors were the primary focus of institutional surveys, with significant attention also given to cyclical sectors like basic chemicals [1] - Institutions are optimistic about investment opportunities in humanoid robots, upstream AI infrastructure, and certain chemical sector stocks that offer high elasticity and dividends [1] Group 2 - In January 2026, domestic automobile sales reached 2.346 million units, with the top ten companies accounting for 1.962 million units, representing 83.6% of total sales, indicating a high concentration in the market [2] - The automotive market is characterized by "steady start and structural differentiation," with increased competition among top manufacturers as they launch new products and technologies [2] - The pharmaceutical and biotechnology sectors saw 80 companies receive institutional surveys, with a focus on brain-computer interface stocks and the trend of innovative drugs going global [2] Group 3 - Several securities firms have held spring strategy meetings earlier than usual, reflecting changes in the competitive landscape of the industry [3] - The shift from "commission for research" to "service for income" is becoming more pronounced among brokerage firms [3] - The AI industry is entering a more pragmatic phase, focusing on revenue and profit, with significant investment opportunities in AI inference computing and domestic AI chips [3] Group 4 - Lithium carbonate futures surged by 11.83% to a high of 187,700 yuan/ton, driven by Zimbabwe's adjustments to lithium export policies, which may tighten global supply in the short term [4] - UBS predicts a potential third price cycle for lithium, raising the average price expectation for 2026 to around 180,000 yuan/ton [4] Group 5 - The A-share merger and acquisition market remains vibrant, with over 500 transactions disclosed since the beginning of the year, totaling over 100 billion yuan [5] - More than 50% of these transactions are driven by industrial synergy, highlighting a core market trend [5] - The hard technology sector is a primary battleground for mergers and acquisitions, with increased participation from the Sci-Tech Innovation Board and the Growth Enterprise Market [5] Group 6 - The Hong Kong Stock Exchange reported record highs in trading volume and revenue for 2025, reaffirming its position as a global leader in new stock financing [6] - The exchange aims to enhance market convenience and competitiveness while continuing to invest strategically in emerging business areas [6] - Export-oriented companies are actively implementing measures to hedge against currency risks amid fluctuations in the renminbi exchange rate [6] Group 7 - Regions like Guangdong, Anhui, and Hubei are strategically positioning themselves in advanced fields such as AI, quantum technology, and high-end manufacturing [7] - The development of future industries relies heavily on original innovation and disruptive technologies, which are still in early stages [7] - Policies are increasingly systematic and comprehensive, supporting innovation from inception to market application [7] Group 8 - NIO's chip subsidiary, Anhui Shenji Technology Co., completed its first round of equity financing, raising 2.257 billion yuan, with a post-investment valuation nearing 10 billion yuan [8] - The financing attracted diverse capital participation, including state-owned capital and semiconductor industry funds, indicating market confidence in the company's technology and production capabilities [8] - The involvement of local state capital aligns with Hefei's ongoing investment in the integrated circuit industry [8]